Response to mTOR inhibition: activity of eIF4E predicts sensitivity in cell lines and acquired changes in eIF4E regulation in breast cancer

BackgroundInhibitors of the kinase mTOR, such as rapamycin and everolimus, have been used as cancer therapeutics with limited success since some tumours are resistant. Efforts to establish predictive markers to allow selection of patients with tumours likely to respond have centred on determining phosphorylation states of mTOR or its targets 4E-BP1 and S6K in cancer cells. In an alternative approach we estimated eIF4E activity, a key effector of mTOR function, and tested the hypothesis that eIF4E activity predicts sensitivity to mTOR inhibition in cell lines and in breast tumours.ResultsWe found a greater than three fold difference in sensitivity of representative colon, lung and breast cell lines to rapamycin. Using an assay to quantify influences of eIF4E on the translational efficiency specified by structured 5'UTRs, we showed that this estimate of eIF4E activity was a significant predictor of rapamycin sensitivity, with higher eIF4E activities indicative of enhanced sensitivity. Surprisingly, non-transformed cell lines were not less sensitive to rapamycin and did not have lower eIF4E activities than cancer lines, suggesting the mTOR/4E-BP1/eIF4E axis is deregulated in these non-transformed cells. In the context of clinical breast cancers, we estimated eIF4E activity by analysing expression of eIF4E and its functional regulators within tumour cells and combining these scores to reflect inhibitory and activating influences on eIF4E. Estimates of eIF4E activity in cancer biopsies taken at diagnosis did not predict sensitivity to 11-14 days of pre-operative everolimus treatment, as assessed by change in tumour cell proliferation from diagnosis to surgical excision. However, higher pre-treatment eIF4E activity was significantly associated with dramatic post-treatment changes in expression of eIF4E and 4E-binding proteins, suggesting that eIF4E is further deregulated in these tumours in response to mTOR inhibition.ConclusionsEstimates of eIF4E activity predict sensitivity to mTOR inhibition in cell lines but breast tumours with high estimated eIF4E activity gain changes in eIF4E regulation in order to enhance resistance.

[1]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[2]  N. Gray,et al.  Regulation of protein synthesis by mRNA structure , 1994, Molecular Biology Reports.

[3]  Funda Meric-Bernstam,et al.  Targeting the mTOR signaling network for cancer therapy. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  V. Speirs,et al.  Combined analysis of eIF4E and 4E-binding protein expression predicts breast cancer survival and estimates eIF4E activity , 2009, British Journal of Cancer.

[5]  R. Motzer,et al.  Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial , 2008, The Lancet.

[6]  V. Speirs,et al.  Expression of oestrogen receptor beta isoforms is regulated by transcriptional and post-transcriptional mechanisms. , 2010, The Biochemical journal.

[7]  M. Kasuga,et al.  Regulation of eIF-4E BP1 Phosphorylation by mTOR* , 1997, The Journal of Biological Chemistry.

[8]  F. Couch,et al.  17q23 amplifications in breast cancer involve the PAT1, RAD51C, PS6K, and SIGma1B genes. , 2000, Cancer research.

[9]  R. Lackman,et al.  Phospho-S6 ribosomal protein: a potential new predictive sarcoma marker for targeted mTOR therapy , 2008, Modern Pathology.

[10]  Suzanne F. Jones,et al.  Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  A. Gingras,et al.  The insulin-induced signalling pathway leading to S6 and initiation factor 4E binding protein 1 phosphorylation bifurcates at a rapamycin-sensitive point immediately upstream of p70s6k , 1997, Molecular and cellular biology.

[12]  P. Miron,et al.  Rapamycin inhibits proliferation of estrogen-receptor-positive breast cancer cells. , 2007, The Journal of surgical research.

[13]  P. Houghton,et al.  4E-binding Proteins, the Suppressors of Eukaryotic Initiation Factor 4E, Are Down-regulated in Cells with Acquired or Intrinsic Resistance to Rapamycin* , 2002, The Journal of Biological Chemistry.

[14]  Suzanne F. Jones,et al.  Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  A. Gingras,et al.  Regulation of translation initiation by FRAP/mTOR. , 2001, Genes & development.

[16]  A. Gingras,et al.  Phosphorylation of eucaryotic translation initiation factor 4B Ser422 is modulated by S6 kinases , 2004, The EMBO journal.

[17]  Nahum Sonenberg,et al.  Dissecting the role of mTOR: lessons from mTOR inhibitors. , 2010, Biochimica et biophysica acta.

[18]  David McDermott,et al.  Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. , 2007, The New England journal of medicine.

[19]  G. Mills,et al.  Determinants of Rapamycin Sensitivity in Breast Cancer Cells , 2004, Clinical Cancer Research.

[20]  L. Gesualdo,et al.  Sirolimus for Kaposi's sarcoma in renal-transplant recipients. , 2005, The New England journal of medicine.

[21]  R. Pearson,et al.  Coordinate regulation of ribosome biogenesis and function by the ribosomal protein S6 kinase, a key mediator of mTOR function , 2007, Growth factors.

[22]  A. Gingras,et al.  Human eukaryotic translation initiation factor 4G (eIF4G) recruits Mnk1 to phosphorylate eIF4E , 1999, The EMBO journal.

[23]  M. Kozak,et al.  An analysis of vertebrate mRNA sequences: intimations of translational control , 1991, The Journal of cell biology.

[24]  R. Abraham,et al.  A new pharmacologic action of CCI-779 involves FKBP12-independent inhibition of mTOR kinase activity and profound repression of global protein synthesis. , 2008, Cancer research.

[25]  N. Sonenberg,et al.  mRNAs containing extensive secondary structure in their 5′ non‐coding region translate efficiently in cells overexpressing initiation factor eIF‐4E. , 1992, The EMBO journal.

[26]  R. DePinho,et al.  The LKB1 tumor suppressor negatively regulates mTOR signaling. , 2004, Cancer cell.

[27]  V. Speirs,et al.  Differential regulation of oestrogen receptor β isoforms by 5′ untranslated regions in cancer , 2009, Journal of cellular and molecular medicine.

[28]  J. Going,et al.  Efficiently estimated histologic cell counts. , 1994, Human pathology.

[29]  T. Haystead,et al.  Sites That Govern Translational Repression Phosphorylation of Phas-i in Five (s/t)p Multiple Mechanisms Control , 2022 .

[30]  Y. Baba,et al.  Usefulness of the 5' region of the cDNA encoding acidic ribosomal phosphoprotein P0 conserved among rats, mice, and humans as a standard probe for gene expression analysis in different tissues and animal species. , 2007, Journal of biochemical and biophysical methods.

[31]  S. Gygi,et al.  Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism. , 1999, Genes & development.

[32]  S. Signoretti,et al.  Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma. , 2007, Clinical genitourinary cancer.

[33]  A. Gingras,et al.  Rapamycin blocks the phosphorylation of 4E‐BP1 and inhibits cap‐dependent initiation of translation. , 1996, The EMBO journal.

[34]  K. Borden,et al.  Controlling Gene Expression through RNA Regulons: The Role of the Eukaryotic Translation Initiation Factor eIF4E , 2007, Cell cycle.

[35]  W. Weichert,et al.  Phospho-mTOR and phospho-4EBP1 in endometrial adenocarcinoma: association with stage and grade in vivo and link with response to rapamycin treatment in vitro , 2009, Journal of Cancer Research and Clinical Oncology.

[36]  T. Hughes,et al.  Cross-talk between pRb/E2F and Wnt/beta-catenin pathways: E2F1 induces axin2 leading to repression of Wnt signalling and to increased cell death. , 2005, Experimental cell research.

[37]  J. Bartlett,et al.  The mammalian target of rapamycin inhibitor everolimus (RAD001) in early breast cancer: results of a pre-operative study , 2011, Breast Cancer Research and Treatment.

[38]  J. Avruch,et al.  Dissociation of raptor from mTOR is a mechanism of rapamycin‐induced inhibition of mTOR function , 2004, Genes to cells : devoted to molecular & cellular mechanisms.

[39]  T. Hughes,et al.  Expression of axin2 Is Regulated by the Alternative 5′-Untranslated Regions of Its mRNA* , 2005, Journal of Biological Chemistry.

[40]  P. Houghton,et al.  Studies on the mechanism of resistance to rapamycin in human cancer cells. , 1998, Molecular pharmacology.

[41]  K. Shokat,et al.  Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E. , 2010, Cancer cell.

[42]  A. Levine,et al.  The coordinate regulation of the p53 and mTOR pathways in cells. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[43]  S K Burley,et al.  Hierarchical phosphorylation of the translation inhibitor 4E-BP1. , 2001, Genes & development.

[44]  G. Knoll,et al.  Conversion From Calcineurin Inhibitors to Sirolimus for Chronic Renal Allograft Dysfunction: A Systematic Review of the Evidence , 2006, Transplantation.

[45]  K. Borden,et al.  eIF4E promotes nuclear export of cyclin D1 mRNAs via an element in the 3′UTR , 2005, The Journal of cell biology.

[46]  G. Pond,et al.  A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas , 2006, British Journal of Cancer.

[47]  S. Schreiber,et al.  Identification of an 11-kDa FKBP12-rapamycin-binding domain within the 289-kDa FKBP12-rapamycin-associated protein and characterization of a critical serine residue. , 1995, Proceedings of the National Academy of Sciences of the United States of America.